FDA scrutiny over compounded GLP-1 medications is expanding rapidly, moving well beyond traditional advertising oversight. Regulators are now taking a direct look at the supply chain—specifically where Active Pharmaceutical Ingredients (APIs) originate and whether compounding entities meet strict federal requirements.

For medical spa owners and healthcare practitioners, relying solely on a partner pharmacy to navigate regulatory obligations creates significant liability. Securing your practice requires a proactive audit of your operational, contractual, and marketing practices surrounding GLP-1 treatments.

Key Areas of Regulatory Exposure

When FDA inquiries, licensing board investigations, patient disputes, or pharmacy conflicts arise, compliance oversights quickly become costly. Practices offering compounded GLP-1s should immediately evaluate the following operational touchpoints:

• Pharmacy Vetting: Who is physically compounding the medication, and what is their licensure status across the jurisdictions where you operate?

• Ingredient Sourcing: Where is the API originating, and is there verifiable documentation confirming it meets federal standard specifications?

• Contractual Protections: What specific indemnification, representations, and liability allocations exist in your written agreements with the compounding pharmacy?

• Patient Disclosures: What explicit representations are being made to patients during consultations and within informed consent documentation regarding the nature of compounded formulations?

• Digital Marketing & Website Accuracy: Does your website and promotional material clearly distinguish compounded GLP-1 formulations from FDA-approved brand-name alternatives?

Proactive Steps for Practice Owners

If compounded GLP-1 treatments form a meaningful segment of your practice, waiting for an enforcement action or inquiry is a high-risk strategy.

At MDRXLaw, we offer a fixed-scope GLP-1 compliance review tailored for pharmacies, med spas, and telehealth companies. Our review evaluates patient-facing advertising, supply chain sourcing, vendor agreements, and operational risk, delivering a clear assessment of issues that require remediation or clarification. To learn more about our fixed-fee GLP-1 compliance review, contact our healthcare team at 212.668.0200 or via email at info@mdrxlaw.com.